GlassScriptPhysician profile
Bardia Sadr
NPI 1912398785
$1,952.17
in general payments reported to CMS, 2019-2025
22 companies · $774 in 2025
The $774 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $148 · 2023: $246 · 2024: $534 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $866.29 | 2021-2025 | Spravato |
| Inari Medical, INC. | $245.76 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Shionogi INC | $123.86 | 2024 | Fetroja |
| Novo Nordisk INC | $79.52 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $60.46 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $51.13 | 2024 | |
| Abbott Laboratories | $50.71 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $50.37 | 2024 | Nuedexta, Rexulti |
| Lilly USA, LLC | $48.70 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $42.43 | 2025 | Airsupra |
| Dexcom, INC. | $39.66 | 2024-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $39.26 | 2025 | Vowst |
| Almatica Pharma LLC | $35.04 | 2024 | Loreev Xr |
| Radius Health, INC. | $32.42 | 2025 | Tymlos |
| Lundbeck LLC | $29.10 | 2024-2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $29.01 | 2025 | Urolift |
| Vivus LLC | $27.59 | 2025 | Pancreaze |
| Scilex Pharmaceuticals INC. | $23.19 | 2024 | |
| Exact Sciences Corporation | $21.57 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2025 | |
| Sumitomo Pharma America, INC. | $19.44 | 2024 | Gemtesa |
| Tolmar, INC. | $16.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bardia Sadr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.